On October 22, 2026, the U.S. FDA announced traditional approval of pembrolizumab (Keytruda) and pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic TMB-H solid tumors that progressed after prior treatment and lack satisfactory alternatives. This approval expands therapeutic options for systemic cancer therapy in this patient population and underscores ongoing advancements in precision oncology driven by tumor mutational burden markers.
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
<p>On October 22, 2026, the U.S. FDA announced traditional approval of pembrolizumab (Keytruda) and pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic TMB-H solid tumors that progressed after prior treatment and lack satisfactory alternatives. This approval expands therape...
- Published date: 04-11-2026 11:02 AM
Read More
On October 22, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda), including the formulation with berahyaluronidase alfa-pmph (Keytruda Qlex), for the treatment of certain solid tumors.
This approval targets adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors that have progressed following prior treatment and for whom no satisfactory alternative options exist.
The decision reflects the FDA's commitment to providing new treatment options in the management of advanced cancers characterized by high tumor mutational burden, supporting clinicians in systemic cancer therapy decisions.
Want to join the conversation?